BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi Sells 2,320 Shares

BioSyent Inc. (CVE:RX) Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00.

BioSyent Stock Performance

Shares of CVE:RX opened at C$11.00 on Wednesday. The company has a market cap of C$127.49 million, a price-to-earnings ratio of 18.33 and a beta of 0.93. The company has a 50-day moving average price of C$10.37 and a 200-day moving average price of C$9.52. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. BioSyent Inc. has a 12 month low of C$7.66 and a 12 month high of C$11.45.

BioSyent (CVE:RX) last released its quarterly earnings results on Monday, August 26th. The company reported C$0.13 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of C$0.13. BioSyent had a net margin of 21.14% and a return on equity of 20.88%. The company had revenue of C$8.95 million during the quarter, compared to the consensus estimate of C$8.80 million. As a group, equities analysts anticipate that BioSyent Inc. will post 0.6785935 EPS for the current year.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.